Advanced Care: Chemical Menopause and Surgical Options

For a small number of people, standard treatments like SSRIs or birth control do not provide enough relief. When PMDD remains severe and life-altering despite these efforts, it is considered refractory ^[1]. In these cases, advanced treatments aim to “turn off” the hormonal cycle entirely to stop the biological trigger at its source ^[2][3].

Chemical Menopause: GnRH Agonists

GnRH agonists (such as leuprolide or goserelin) are medications that put the body into a temporary, reversible state of “chemical menopause” by stopping the ovaries from producing cyclical estrogen and progesterone ^[2][4].

Because GnRH agonists initially stimulate the hormone receptors before shutting them down, many patients experience a temporary “flare” or worsening of symptoms in the first few weeks before suppression takes effect. However, research shows that for many with PMDD, this total ovarian suppression can ultimately eliminate the cyclical “rollercoaster” of symptoms ^[3][5]. Because these medications are powerful and carry side effects, they are typically used as a short-term “reset” or as a diagnostic trial rather than a lifelong solution ^[2][6].

The Role of “Add-Back” Therapy

Because low estrogen levels can cause hot flashes, night sweats, and—over time—bone thinning (osteoporosis), doctors often prescribe add-back therapy ^[2][7]. This involves taking very small, steady doses of hormones while on the GnRH agonist ^[2].

This creates a delicate balance. Since PMDD is caused by a sensitivity to hormone shifts, reintroducing these hormones can sometimes “re-trigger” the very symptoms the medication was meant to stop ^[3][2]. Progesterone, in particular, is often more closely associated with a return of irritability and mood swings than estrogen ^[3]. Importantly, if you have a uterus, systemic estrogen requires adequate progestogen or another form of endometrial protection to prevent abnormal cell growth in the uterine lining; your specialist will work to find a tolerable add-back formulation that balances PMDD symptom relief with endometrial and bone protection.

The Surgical Option: Oophorectomy

A bilateral oophorectomy (surgical removal of both ovaries) is an irreversible, last-resort option for the most severe cases of PMDD ^[8][4]. Removing the ovaries permanently stops the cyclical hormone production driving the condition.

This procedure causes permanent menopause and is often combined with a hysterectomy (removal of the uterus) ^[9][10]. It is important to note that a hysterectomy on its own does not treat PMDD, as it does not stop the ovaries from cycling. Instead, it is typically performed alongside oophorectomy so that the patient can safely take estrogen-only HRT afterward, completely avoiding the need for progestogen (which may trigger PMDD symptoms) ^[9].

The Medical Trial

Before ever considering permanent surgery, medical guidelines and experts recommend a prospective trial of a GnRH agonist to act as a “surgical simulation” ^[11][4]. While a trial lasting about 6 months is often discussed, the actual duration varies by guideline, specialist judgment, and how well you tolerate the add-back plan. If you do not feel significantly better during chemical menopause, surgery is unlikely to help and may even introduce new, permanent complications ^[4][11].

Long-Term Health Considerations

Entering menopause early—whether through surgery or medication—carries significant long-term health risks that must be managed, and causes the permanent loss of natural fertility (requiring fertility preservation counseling beforehand) ^[7][12].

• Bone Health: Estrogen is vital for maintaining bone density. Without it, the risk of osteoporosis and fractures increases significantly ^[7][13].
• Cardiovascular Health: Early menopause is associated with a higher risk of heart disease and stroke ^[14][12].
• Cognitive and Sexual Health: Early surgical menopause requires evaluating complex long-term risks, including potential cognitive changes and impacts on sexual function or desire ^[15][16].

Because of these risks, people who undergo surgical menopause for PMDD are frequently advised to stay on Hormone Replacement Therapy (HRT) until approximately age 51 (the average age of natural menopause) to help protect their heart and bones ^[7][17]. However, this is not an automatic rule for every patient; it must be balanced against individual contraindications and the risk of PMDD symptom recurrence. Your care team will need to monitor your specific health risks closely ^[7][12].

Choosing this path is a major medical decision. It requires careful, daily symptom tracking during your “trial” phase to ensure that the trade-offs of menopause are worth the relief from PMDD ^[18][3].